Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus EXTRANEAL.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Delflex with 4.25% dextrose is a peritoneal dialysis solution that removes waste products, electrolytes, and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient, drawing fluid and solutes from the capillaries into the peritoneal cavity.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD).
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
Not applicable as a combination solution; glucose half-life ~1.5-2 hours in normal renal function; prolonged in renal impairment.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Renal: >90% as unchanged glucose and electrolytes; negligible biliary/fecal elimination.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution